Safety Evaluation of Allogeneic Umbilical Cord Blood Mononuclear Cell Therapy for Degenerative Conditions

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2010 Aug 5

PMID 20682053

Citations 29

Authors

Wan-Zhang Yang

Yun Zhang

Fang Wu

Wei-Ping Min

Boris Minev

Min Zhang

Xiao-Ling Luo

Famela Ramos

Thomas E Ichim

Neil H Riordan

Xiang Hu

Affiliations

Soon will be listed here.

Abstract

Background: The current paradigm for cord blood transplantation is that HLA matching and immune suppression are strictly required to prevent graft versus host disease (GVHD). Immunological arguments and historical examples have been made that the use of cord blood for non-hematopoietic activities such as growth factor production, stimulation of angiogenesis, and immune modulation may not require matching or immune suppression.

Methods: 114 patients suffering from non-hematopoietic degenerative conditions were treated with non-matched, allogeneic cord blood. Doses of 1-3 x 10(7) cord blood mononuclear cells per treatment, with 4-5 treatments both intrathecal and intravenously were performed. Adverse events and hematological, immunological, and biochemical parameters were analyzed for safety evaluation.

Results: No serious adverse effects were reported. Hematological, immunological, and biochemical parameters did not deviate from normal ranges as a result of therapy.

Conclusion: The current hematology-based paradigm of need for matching and immune suppression needs to be revisited when cord blood is used for non-hematopoietic regenerative purposes in immune competent recipients.

Citing Articles

A Biosafety Study of Human Umbilical Cord Blood Mononuclear Cells Transduced with Adenoviral Vector Carrying Human Vascular Endothelial Growth Factor cDNA In Vitro.

Salafutdinov I, Gatina D, Markelova M, Garanina E, Malanin S, Gazizov I Biomedicines. 2023; 11(7).

PMID: 37509661 PMC: 10377014. DOI: 10.3390/biomedicines11072020.

Induction of Angiogenesis by Genetically Modified Human Umbilical Cord Blood Mononuclear Cells.

Gatina D, Gazizov I, Zhuravleva M, Arkhipova S, Golubenko M, Gomzikova M Int J Mol Sci. 2023; 24(5).

PMID: 36901831 PMC: 10002409. DOI: 10.3390/ijms24054396.

Umbilical cord blood stem cells transplantation in a patient with severe progressive supranuclear palsy: a case report.

Li H, Yuan F, Du Y, Pan T, Wen W, Li S J Med Case Rep. 2021; 15(1):574.

PMID: 34844635 PMC: 8628425. DOI: 10.1186/s13256-021-03139-z.

Cell Therapy for Neurological Disorders: The Perspective of Promising Cells.

Liu D, Bobrovskaya L, Zhou X Biology (Basel). 2021; 10(11).

PMID: 34827135 PMC: 8614777. DOI: 10.3390/biology10111142.

Evaluation of Direct and Cell-Mediated Lactoferrin Gene Therapy for the Maxillofacial Area Abscesses in Rats.

Agatieva E, Ksembaev S, Sokolov M, Markosyan V, Gazizov I, Tsyplakov D Pharmaceutics. 2021; 13(1).

PMID: 33406760 PMC: 7823524. DOI: 10.3390/pharmaceutics13010058.

References

Harris D . Non-haematological uses of cord blood stem cells. Br J Haematol. 2009; 147(2):177-84. DOI: 10.1111/j.1365-2141.2009.07767.x. View

Moon Y, Yoon H, Lee M, Jang I, Lee D, Lee J . Multipotent progenitor cells derived from human umbilical cord blood can differentiate into hepatocyte-like cells in a liver injury rat model. Transplant Proc. 2009; 41(10):4357-60. DOI: 10.1016/j.transproceed.2009.08.053. View

Liu W, Chen C, Foo N, Huang H, Wang J, Chen S . Human umbilical cord blood cells protect against hypothalamic apoptosis and systemic inflammation response during heatstroke in rats. Pediatr Neonatol. 2009; 50(5):208-16. DOI: 10.1016/S1875-9572(09)60065-6. View

Haller M, Wasserfall C, McGrail K, Cintron M, Brusko T, Wingard J . Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care. 2009; 32(11):2041-6. PMC: 2768209. DOI: 10.2337/dc09-0967. View

Ichim T, Alexandrescu D, Solano F, Lara F, de Necochea Campion R, Paris E . Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol. 2009; 260(2):75-82. DOI: 10.1016/j.cellimm.2009.10.006. View

Hwang W, Chen S, Lin C, Chang H, Chen W, Lin M . Human umbilical cord blood-derived CD34+ cells can be used as a prophylactic agent for experimental heatstroke. J Pharmacol Sci. 2008; 106(1):46-55. DOI: 10.1254/jphs.fp0071567. View

Bachstetter A, Pabon M, Cole M, Hudson C, Sanberg P, Willing A . Peripheral injection of human umbilical cord blood stimulates neurogenesis in the aged rat brain. BMC Neurosci. 2008; 9:22. PMC: 2268935. DOI: 10.1186/1471-2202-9-22. View

Xiao J, Nan Z, Motooka Y, Low W . Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury. Stem Cells Dev. 2006; 14(6):722-33. DOI: 10.1089/scd.2005.14.722. View

Ghen M, Roshan R, Roshan R, Blyweiss D, Corso N, Khalili B . Potential clinical applications using stem cells derived from human umbilical cord blood. Reprod Biomed Online. 2006; 13(4):562-72. DOI: 10.1016/s1472-6483(10)60646-3. View

10.

Xing Y, Shen L, Li H, Zhang Y, Zhao L, Zhao S . Optimal time for human umbilical cord blood cell transplantation in rats with myocardial infarction. Chin Med J (Engl). 2010; 122(23):2833-9. View

11.

Garbuzova-Davis S, Willing A, Zigova T, Saporta S, Justen E, Lane J . Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. J Hematother Stem Cell Res. 2003; 12(3):255-70. DOI: 10.1089/152581603322022990. View

12.

Hutton J, Gargett T, Sadlon T, Bresatz S, Brown C, Zola H . Development of CD4+CD25+FoxP3+ regulatory T cells from cord blood hematopoietic progenitor cells. J Leukoc Biol. 2008; 85(3):445-51. DOI: 10.1189/jlb.1008620. View

13.

Gratwohl A, Baldomero H . Trends of hematopoietic stem cell transplantation in the third millennium. Curr Opin Hematol. 2009; 16(6):420-6. DOI: 10.1097/MOH.0b013e328330990f. View

14.

Riordan N, Chan K, Marleau A, Ichim T . Cord blood in regenerative medicine: do we need immune suppression?. J Transl Med. 2007; 5:8. PMC: 1796850. DOI: 10.1186/1479-5876-5-8. View

15.

Ichim T, Solano F, Brenes R, Glenn E, Chang J, Chan K . Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy. Reprod Biomed Online. 2008; 16(6):898-905. DOI: 10.1016/s1472-6483(10)60159-9. View

16.

Yoo K, Jang I, Lee M, Kim H, Yang M, Eom Y . Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol. 2009; 259(2):150-6. DOI: 10.1016/j.cellimm.2009.06.010. View

17.

Hwang J, Shim S, Seok O, Lee H, Woo S, Kim B . Comparison of cytokine expression in mesenchymal stem cells from human placenta, cord blood, and bone marrow. J Korean Med Sci. 2009; 24(4):547-54. PMC: 2719209. DOI: 10.3346/jkms.2009.24.4.547. View

18.

Riordan N, Ichim T, Min W, Wang H, Solano F, Lara F . Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med. 2009; 7:29. PMC: 2679713. DOI: 10.1186/1479-5876-7-29. View

19.

Peng C, Lin H, Lin Y, Tsai C, Yeh T . Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics. 1999; 104(3 Pt 1):476-81. DOI: 10.1542/peds.104.3.476. View

20.

Javed M, Mead L, Prater D, Bessler W, Foster D, Case J . Endothelial colony forming cells and mesenchymal stem cells are enriched at different gestational ages in human umbilical cord blood. Pediatr Res. 2008; 64(1):68-73. DOI: 10.1203/PDR.0b013e31817445e9. View